Tobin and colleagues show that both inhibition and excessive production of the inflammatory mediator TNFa impact the pathogenesis of tuberculosis (TB) and the response to therapy. Identifying a critical role for the genetically determined balance between pro-and anti-inflammatory eicosanoids in regulating TNFa levels provides a roadmap to tailored TB treatment based on host genotype.
Mycobacterium tuberculosis (Mtb) has been our unwelcome companion for millennia, using humans to ''walk'' out of Africa, ''sail'' out of Europe and ''canoe'' across North America. In order to infect an estimated one-third of the world's population and cause 8.1 million new cases of active TB annually (World Health Organization, 2011) , Mtb must withstand and exploit host immune responses to ensure its survival and transmission. In turn, the human immune response has been calibrated to optimize survival in the face of this intracellular threat, as exemplified by the immune control and absence of pathology that characterize latent TB infection. Infection develops into disease due to bacterial dissemination resulting from inadequate protective immunity, whereas tissue pathology is caused by an overly vigorous yet ineffective host response. Identifying pathways that regulate and potentially dissociate protection from pathology will aid rational development of new interventions for treatment and vaccination. In this issue of Cell, Tobin and colleagues dissect a pivotal genetic balance that maintains the host between the two extremes of failed immunity and damaging hyperimmunity (Tobin et al., 2012) .
The inhibition of macrophage apoptosis and the concomitant induction of necrosis is currently emerging as a pathway that is important for Mtb virulence, allowing for bacterial spread between cells prior to the induction of an adaptive immune response. In contrast, avirulent mycobacteria induce macrophage apoptosis, resulting in prompt development of a protective immune response. Converging results from different labs have revealed that the arachidonic acid metabolites, eicosanoids, lipoxins, and leukotrienes influence cell death patterns following mycobacterial infection (Behr et al., 2010) . Lipoxin A4 (LXA4), produced through the action of lipoxygenase enzyme, acts as an anti-inflammatory mediator of mycobacterial-induced necrosis of infected macrophages; its key role is evidenced by the greater resistance of LXA4-deficient 5-lipoxygense knockout (Alox5 À/À ) mice to Mtb infection (Behar et al., 2011; Chen et al., 2008; Divangahi et al., 2010) .
Studying the natural host-pathogen pair of M. marinum in zebrafish, the Ramakrishnan laboratory previously reported on the susceptibility to infection of mutant fish lacking the Leukotriene A4 (LTA4) hydrolase enzyme (Tobin et al., 2010) , responsible for converting LTA4 to proinflammatory Leukotriene B4 (LTB4). This hypersusceptibility was due to increased LXA4 levels, which resulted in decreased transcription of TNFa and the promotion of an anti-inflammatory environment. Interestingly, humans heterozygous for SNPs in the Leukotriene A4 hydrolase (lta4h) gene were relatively protected against tuberculosis in comparison to either homozygote genotype. In the current report, Tobin and colleagues investigate the mechanisms underlying heterozygote advantage in the eicosanoid pathway (Tobin et al., 2012) . Using lta4h RNA injections into one-cell embryos and lta4h antisense oligonucleotide, they created LTA4H-high and LTA4H-low animals. The LTA4H-low phenotype was characterized by excess anti-inflammatory LXA4 and TNFa deficiency, whereas the LTAH4-high phenotype had increased proinflammatory LTB4 and excess TNFa. Remarkably, both phenotypes succumbed to M. marinum infection, with similar increases in bacterial burden. This susceptibility was reversed following recombinant TNFa administration and TNFa blockade in the anti-inflammatory (LTA4H-low) and proinflammatory (LTA4H-high) fish, respectively. Furthermore, pharmacologic inhibition of lipoxins reduced the infection burden of LTA4H-low animals, whereas pharmacologic suppression of inflammation (with the glucocorticoid dexamethasone or aspirin) reduced the infection burden of LTA4H-high animals; all effects were mediated by TNFa, with modest changes determining the outcomes of infection.
The marked inflammatory pathology and lymphocyte infiltration in TB meningitis (TBM) have stimulated clinical trials of immunosuppressive therapy aimed at dampening overexuberant inflammation in these patients suffering the most severe form of TB (Thwaites et al., 2004) . However, the response to treatment with dexamethasone, on aggregate, has been at best modest (Prasad and Singh, 2008) . Might such ambiguous trial results be explained by the dichotomous LTA4H genotype-dependent action of dexamethasone? To investigate this, the authors identified a functional SNP in the promoter region of the lta4h gene that influences mRNA transcription. Next, by stratifying TBM patients from a historic randomized trial by lta4h genotype, they revealed both different outcomes of disease and starkly different responses to dexamethasone. Overall, heterozygotes fared best. Among patients not treated with dexamethasone, the proinflammatory homozygous (TT) LTA4H-genotype had the worst outcome; however, the survival benefit of dexamethasone was greatest for this genotype. Conversely, dexamethasone may have worsened outcome in patients with the anti-inflammatory homozygous (CC) LTA4H-genotype. The elegant translation of the zebrafish findings to human therapeutic efficacy has important practical implications for clinical management of TB as well as potentially far-reaching evolutionary implications for host heterozygote advantage in infectious diseases. 
. Two Sides of TNFa
Mycobacterium tuberculosis enters and exits the lung. In most cases, infection is contained in the thorax, resulting in either asymptomatic latent infection (in $90%) or pulmonary TB (in $10%). In some cases, host containment of bacteria is compromised, and bacteria disseminate outside the thorax to distant sites, including the meninges (Tuberculous meningitis). In a host with genetically determined high expression of LTA4 Hydrolase (LTA4H) enzyme (TT homozygote, left) or deficient in LTA4H (CC homozygote, right), excess proinflammatory LTB4 (left) and anti-inflammatory LXA4 (right) lead to an excess or reduced levels of TNFa, respectively. Despite the polar opposites of a failed immune response in the case of reduced TNFa (right) and an exuberant inflammatory response with excessive TNFa (left), a similar outcome of macrophage necrosis and bacterial growth ensues. Immunomodulatory pharmacotherapy with dexamethasone to dampen the excessive inflammation reduces disease severity only in TT homozygous (LTA4H-high) individuals and potentially has an adverse effect in CC homozygous individuals. Further studies should provide insight into how other factors and processes, such as, for example, mycobacterial lineage and the adaptive immune response, affect the TNFa balance maintained by the host eicosanoid pathway.
Taken together with the authors' previous findings that heterozygosity in the lta4h locus is associated with resistance to TB and multibacillary leprosy (Tobin et al., 2010) , the present study makes a strong case for heterozygote advantage in mycobacterial disease, with balancing selection maintaining allelic variation in the eicosanoid pathway to modulate balanced TNFa-mediated responses to infection. Because resistance to TB involves pathways that are important for host responses to other diseases, investigating the eicosanoid pathway in infections with other intracellular pathogens may prove fruitful.
Given that genotype determined outcome of TBM, should not host phenotype also be predictive? For example, can clinical outcome or response to dexamethasone be stratified by TNFa or eicosanoid levels in serum or cerebrospinal fluid? How do TNFa levels change in response to dexamethasone in TBM patients of the homozygous (TT) genotype? Unfortunately, these questions cannot be addressed in this retrospective analysis of a clinical trial from almost a decade ago. These and other analytes should be measured prospectively in future clinical trials of TBM and other forms of TB to define the mechanism of the observed genetic effects; if it is the same as in zebrafish, then these could prove to be useful biomarkers to individualize therapy.
The consistency of zebrafish findings with data from human studies provides compelling evidence for the validity of this experimental model. However, when defining the relative importance of this versus other pathways for humans with TB, the effect of the more developed mammalian adaptive immune system may be critical, especially given that activated lymphocytes are a predominant source of TNFa. The eicosanoid/prostanoid pathway influences the development of cellular immunity in the murine model of TB (Divangahi et al., 2010) , but how the lta4h gene affects adaptive immunity in humans remains to be investigated. Furthermore, dexamethasone has pleiotropic immunosuppressive effects encompassing both innate and adaptive immunity through transactivation of antiinflammatory genes and transrepression of proinflammatory proteins. Whether the therapeutic effects of dexamethasone are specifically mediated via the eicosanoid pathway and TNFa in humans will thus require further investigation, as will assaying the effects of drugs like aspirin and anti-TNFa agents. Other questions that now need to be addressed include the role of these immune processes through time (progression from infection to disease), over space (different anatomic sites of TB disease), and across species (when comparing hosts with different immune systems). Can pharmacologic immune-modulation favor control of infection with minimal host pathology across different forms of TB, and if so, can host genetics predict responsiveness? How do other key factors, such as, for example, adaptive immunity, mycobacterial lineage, and HIV, impact the TNFa balance maintained by the host eicosanoid pathway and susceptibility to severe TB (Figure 1) ?
Regardless of these questions, by establishing the pharmacogenomic basis of immunomodulatory therapy, Tobin et al. herald a new era of personalized medicine in TB. The next step toward informing clinical practice might therefore be a genotype-stratified trial to assess treatment outcome of dexamethasone and/or aspirin in lta4h TT homozygote TB patients compared to standard treatment without immunomodulation in the other two genotypes.
This latest contribution by the Ramakrishnan group conceptually extends the one-dimensional paradigm of susceptibility to mycobacteria. It suggests instead that distinct routes toward optimal immunity depend critically on where one starts, a message that may also inform the quest for a new TB vaccine. These data present a cogent rebuttal to George Bernard Shaw's century-old advice from his play The Doctor's Dilemma: ''There is at bottom only one genuinely scientific treatment for all diseases, and that is to stimulate the phagocytes.'' In light of the present findings, the genuinely scientific solution to the TB doctor's dilemma may become: ''Genotype the phagocyte, then choose the treatment.''
